BR0212151A - Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas - Google Patents

Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas

Info

Publication number
BR0212151A
BR0212151A BR0212151-4A BR0212151A BR0212151A BR 0212151 A BR0212151 A BR 0212151A BR 0212151 A BR0212151 A BR 0212151A BR 0212151 A BR0212151 A BR 0212151A
Authority
BR
Brazil
Prior art keywords
trauma
nerve damage
compounds
conditions resulting
treat conditions
Prior art date
Application number
BR0212151-4A
Other languages
English (en)
Inventor
Mark R Hellberg
Iok-Hou Pang
John M Yanni
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0212151A publication Critical patent/BR0212151A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"USO DE COMPOSTOS PARA TRATAR CONDIçõES RESULTANTES DE DANO AO NERVO CORNEANO APóS CIRURGIAS DE LASIK E OUTRAS OCULARES OU TRAUMAS". A presente invenção refere-se métodos para o tratamento de condições resultantes de dano ao nervo corneano após cirurgias de LASIK e outras oculares ou trauma.
BR0212151-4A 2001-08-29 2002-07-23 Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas BR0212151A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31565201P 2001-08-29 2001-08-29
PCT/US2002/023871 WO2003020281A1 (en) 2001-08-29 2002-07-23 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma

Publications (1)

Publication Number Publication Date
BR0212151A true BR0212151A (pt) 2004-08-24

Family

ID=23225436

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212151-4A BR0212151A (pt) 2001-08-29 2002-07-23 Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas

Country Status (10)

Country Link
EP (1) EP1420791A4 (pt)
JP (1) JP2005502678A (pt)
CN (1) CN1549718A (pt)
AR (1) AR036194A1 (pt)
BR (1) BR0212151A (pt)
CA (1) CA2455896A1 (pt)
MX (1) MXPA04001255A (pt)
PL (1) PL368565A1 (pt)
WO (1) WO2003020281A1 (pt)
ZA (1) ZA200400837B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101076638B1 (ko) * 2003-04-18 2011-10-27 센주 세이야꾸 가부시키가이샤 각막 지각 회복제
ES2234428B1 (es) * 2003-12-09 2006-11-01 Universidad Miguel Hernandez Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva.
KR20070036031A (ko) * 2004-04-23 2007-04-02 센주 세이야꾸 가부시키가이샤 Ｐａｃａｐ 및 이의 유도체를 함유하는 각막 신경세포 형성촉진제
WO2005118582A1 (ja) 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
EP2266559A1 (en) 2005-03-15 2010-12-29 Ono Pharmaceutical Co., Ltd. Therapeutic agent for ophthalmic disease
CN113350326B (zh) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
AU2001261360A1 (en) * 2000-05-10 2001-11-20 Alcon, Inc. R-eliprodil for treating glaucoma

Also Published As

Publication number Publication date
EP1420791A1 (en) 2004-05-26
ZA200400837B (en) 2005-02-02
PL368565A1 (en) 2005-04-04
CN1549718A (zh) 2004-11-24
AR036194A1 (es) 2004-08-18
CA2455896A1 (en) 2003-03-13
MXPA04001255A (es) 2004-05-27
WO2003020281A1 (en) 2003-03-13
EP1420791A4 (en) 2004-09-15
JP2005502678A (ja) 2005-01-27

Similar Documents

Publication Publication Date Title
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE60022544D1 (de) Behandlung von augenerkrankungen
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
HK1038694A1 (zh) 治疗眼、耳、鼻病症的抗生素合成剂
BR9907715A (pt) Composição oftálmica/método para tratamento de lesão córnea e/ou de estesia córnea deteriordada, sìndrome de olho seco, hipolarcrimação e uso de um inibidor de redutase de aldose
BR0212151A (pt) Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
DE602005008935D1 (de) Statine zur behandlung von okularer hypertonie und glaukom
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
DE60135972D1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
BR0017340A (pt) Tratamento de trauma e outras indicações
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
DE69525631D1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
ATE278401T1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
ATE215824T1 (de) Mittel zur verminderung des augeninnendrucks
BRPI0417549A (pt) miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal
BR0212274A (pt) Uso de estrogênios não-feminilizantes como agentes retinoprotetores para o tratamento de glaucoma
BR0215752A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
RU95107870A (ru) Способ лечения послеоперационной цилиохориоидальной отслойки
BR0015486A (pt) Ligandos de neurofilina para tratamento de condições oculares
BR0000016A (pt) Dispositivo para implante intracorneano e processo para tratamento de deformidades da córnea

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired